Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRODIGE 90 / PREDIR-NEOREC
2024-510772-20-00Phase 2Authorised
- Sponsor
- Centre Hospitalier Universitaire Dijon Bourgogne
- Start
- Jul 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of dostarlimab in rectal adenocarcinoma and rectal cancer (2 arms), sponsored by Centre Hospitalier Universitaire Dijon Bourgogne. Primary endpoint: Treatment strategy failure rate at 24 months. Planned start Jul 2024; status: authorised.
02
Drugs
dostarlimab
03
Conditions
rectal adenocarcinomarectal cancer
Beyond the preview
Go deeper on 2024-510772-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-510772-20-00.